MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-12-2024
Agile Therapeutics Cost of Revenue 2011-2026 | AGRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.98 M | 6.84 M | 10.7 M | 282 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 M | 282 K | 6.7 M |
Quarterly Cost of Revenue Agile Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.5 M | 1.68 M | - | 2.48 M | 2.31 M | 2 M | - | 1.42 M | 2.23 M | 1.53 M | - | 2.71 M | 1.14 M | 1.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.71 M | 1.14 M | 1.83 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.05 | -3.67 % | $ 113 M |  Canada |
 |
Jupiter Wellness
JUPW
|
2.69 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
100 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
11 M | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
57.6 M | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
China Pharma Holdings
CPHI
|
4.28 M | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.07 | 0.98 % | $ 23.9 M | USA |